On October 28, 2022, the FDA alerted the country regarding the current shortage of amoxicillin oral powder, which is used in making amoxicillin oral suspension for patients. Amoxicillin is an antibiotic in the penicillin drug class, and it is used to treat a large variety of bacterial infections. It is used frequently in respiratory illnesses experienced by pediatric patients, which have been on the rise in recent months. Respiratory Syncytial Virus (RSV) is a virus that can cause mild cold-like symptoms but can also lead to more serious illness. It is the most common cause of bronchiolitis and pneumonia in young children in the United States. Recently there has been a surge in RSV cases, and while amoxicillin cannot treat viral illness like RSV, it can be used to treat bacterial infections that often develop in patients recovering from RSV. The increasing trend of these infections, along with a move into cold and flu season, has been a large contributor to the shortage. One pharmaceutical company, Sandoz, has a limited supply of amoxicillin while the medication distribution is on allocation by Aurobindo and Teva Pharmaceuticals. Fortunately, Rising Pharma Holding and Hikma Pharmaceuticals have amoxicillin available for current customers. Many pharmacies will have a limited stock of certain strengths of this medication and as a result, pharmacists and providers will have to efficiently work together to prescribe an appropriate dose of amoxicillin based on which products the pharmacy can acquire. As pharmaceutical manufacturers work to increase production, health care providers will continue to optimize the use of available amoxicillin and other treatment options. The amoxicillin shortage is estimated to continue into 2023.